Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | QPCT | Q16769 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 2/20 | 0.47 |
| ▸ | WEE1 | P30291 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6978222 | 0.88 | TSHR (0.50) | TSHRGAAKMT2AQPCTHSD17B10 | |
| SCHEMBL6977534 | 0.87 | TSHR (0.52) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6980842 | 0.87 | TSHR (0.49) | TSHRGAAKMT2AQPCTHSD17B10 | |
| SCHEMBL6982150 | 0.87 | TSHR (0.52) | TSHRGAAKMT2AQPCT | |
| SCHEMBL6980841 | 0.85 | CYP1A2 (0.51) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6981436 | 0.85 | CYP1A2 (0.51) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6981013 | 0.85 | TSHR (0.52) | TSHRSMN1; SMN2GAAKMT2AQPCT | |
| SCHEMBL6972018 | 0.85 | TSHR (0.47) | TSHRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL6976772 | 0.85 | QPCT (0.51) | TSHRGAAKMT2AQPCT | |
| SCHEMBL6982552 | 0.85 | ALDH1A1 (0.50) | TSHRGAAKMT2AQPCTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | LES LABORATORIES SERVIER (FR) | 2003-10-23 | — | — | US | disclosed |
| EP-1346992-A1 | Quinazoline derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199530-A1 | New compounds derived from quinazoline | NQO2, XDH, DRD1 | TSHR 3090/4885CYP1A2 105/4885CYP3A4 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.